See full prescribing information for KEYTRUDA. KEYTRUDA® (pembrolizumab) injection, for intravenous use. Initial U.S. Approval: 2014. --------- ...

The recommended dose of KEYTRUDA is 200 mg administered as an intravenous infusion over. 30 minutes every 3 weeks in combination with lenvatinib 20 mg orally ...

HIGHLIGHTS OF PRESCRIBING INFORMATION. These highlights do not include all the information needed to use. KEYTRUDA safely and effectively. See full prescribing.

KEYTRUDA is indicated for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed ... Prescribing Information · Efficacy · Approved Indications · Dosing

Prescribing Information (PI). View or download the Prescribing Information below, an interactive version will be available soon.

FDA-Approved Indications. KEYTRUDA is a prescription medicine used to treat: a kind of lung cancer called non–small cell lung cancer (NSCLC).

KEYTRUDA, in combination with enfortumab vedotin, is indicated for the first-line treatment of unresectable or metastatic urothelial carcinoma in adults.

HIGHLIGHTS OF PRESCRIBING INFORMATION. These highlights do not include all the information needed to use. KEYTRUDA safely and effectively. See full prescribing.

8 июн. 2023 г. · Classical Hodgkin Lymphoma (cHL). KEYTRUDA® (pembrolizumab) is indicated as monotherapy for the treatment of adult patients.

There are no clinically significant exposure-response relationships for efficacy or safety at pembrolizumab dosages of 200 mg or 2 mg/kg every 3 weeks and 400 ...